Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion

Ann Hematol. 2021 May;100(5):1329-1331. doi: 10.1007/s00277-020-04332-8. Epub 2020 Nov 5.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Bone Marrow / metabolism
  • Bone Marrow / pathology
  • Combined Modality Therapy
  • Cord Blood Stem Cell Transplantation
  • Humans
  • Imatinib Mesylate / therapeutic use*
  • Male
  • Oncogene Proteins, Fusion / genetics*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Receptor, Platelet-Derived Growth Factor beta / genetics*
  • Trans-Activators / genetics*
  • Treatment Outcome
  • Young Adult

Substances

  • EBF1 protein, human
  • Oncogene Proteins, Fusion
  • Trans-Activators
  • Imatinib Mesylate
  • PDGFRB protein, human
  • Receptor, Platelet-Derived Growth Factor beta